ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VRAYLAR
Mood disorders
Psychosis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VRAYLAR Rx

Generic Name and Formulations:
Cariprazine 1.5mg, 3mg, 4.5mg, 6mg; caps.

Company:
Allergan

Therapeutic Use:

Indications for VRAYLAR:

Manic or mixed episodes associated with bipolar I disorder.

Adult:

Initially 1.5mg once daily; increase to 3mg on Day 2; may further adjust by 1.5mg or 3mg increments based on response and tolerability; max 6mg/day. Usual range 3–6mg once daily. Initiating a strong CYP3A4 inhibitor while on Vraylar: reduce Vraylar dose by ½. Initiating Vraylar while already on a strong CYP3A4 inhibitor: give 1.5mg on Days 1 and 3 (no dose on Day 2), then 1.5mg daily from Day 4 onward; increase to max 3mg daily. May need to increase Vraylar dose after withdrawing inhibitor.

Children:

Not established.

Warnings/Precautions:

Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Discontinue immediately if neuroleptic malignant syndrome is suspected; treat appropriately. Tardive dyskinesia. Diabetes. Monitor for hyperglycemia, hyperlipidemia; do fasting blood glucose and lipids testing initially and during therapy. Monitor for weight gain, extrapyramidal symptoms, akathisia; consider reducing dose or discontinuing. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Hypovolemia. Dehydration. Perform fall risk assessments when initiating and recurrently on long-term therapy. Cardio- or cerebrovascular disease. Monitor HR and BP. History of seizures. Strenuous exercise. Exposure to extreme heat. Risk for aspiration. Reevaluate periodically. Severe hepatic or renal impairment: not recommended. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers.

Interactions:

See Adults. Potentiated by strong CYP3A inhibitors (eg, itraconazole, ketoconazole). Concomitant CYP3A4 inducers (eg, rifampin, carbamazepine): not recommended. Potentiates antihypertensives. Caution with drugs that interfere with temperature regulation (eg, anticholinergics).

Pharmacological Class:

Atypical antipsychotic.

Adverse Reactions:

Extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, restlessness, dizziness, headache, constipation, abdominal pain, nausea, diarrhea, weight gain, fatigue, fever, tachycardia; orthostatic hypotension, hyperglycemia, dysphagia, others.

Generic Availability:

NO

How Supplied:

Caps—30, 90; Blister packs—7 (1.5mg × 1 + 3mg × 6)

Indications for VRAYLAR:

Schizophrenia.

Adult:

Initially 1.5mg once daily; increase to 3mg on Day 2; may further adjust by 1.5mg or 3mg increments based on response and tolerability; max 6mg/day. Usual range 1.5–6mg once daily. Initiating a strong CYP3A4 inhibitor while on Vraylar: reduce Vraylar dose by ½. Initiating Vraylar while already on a strong CYP3A4 inhibitor: give 1.5mg on Days 1 and 3 (no dose on Day 2), then 1.5mg daily from Day 4 onward; increase to max 3mg daily. May need to increase Vraylar dose after withdrawing inhibitor.

Children:

Not established.

Warnings/Precautions:

Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Discontinue immediately if neuroleptic malignant syndrome is suspected; treat appropriately. Tardive dyskinesia. Diabetes. Monitor for hyperglycemia, hyperlipidemia; do fasting blood glucose and lipids testing initially and during therapy. Monitor for weight gain, extrapyramidal symptoms, akathisia; consider reducing dose or discontinuing. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Hypovolemia. Dehydration. Perform fall risk assessments when initiating and recurrently on long-term therapy. Cardio- or cerebrovascular disease. Monitor HR and BP. History of seizures. Strenuous exercise. Exposure to extreme heat. Risk for aspiration. Reevaluate periodically. Severe hepatic or renal impairment: not recommended. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy. Nursing mothers.

Interactions:

See Adults. Potentiated by strong CYP3A inhibitors (eg, itraconazole, ketoconazole). Concomitant CYP3A4 inducers (eg, rifampin, carbamazepine): not recommended. Potentiates antihypertensives. Caution with drugs that interfere with temperature regulation (eg, anticholinergics).

Pharmacological Class:

Atypical antipsychotic.

Adverse Reactions:

Extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, restlessness, dizziness, headache, constipation, abdominal pain, nausea, diarrhea, weight gain, fatigue, fever, tachycardia; orthostatic hypotension, hyperglycemia, dysphagia, others.

Generic Availability:

NO

How Supplied:

Caps—30, 90; Blister packs—7 (1.5mg × 1 + 3mg × 6)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs